Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kezar Life Sciences (KZR) Invested Capital (2021 - 2025)

Kezar Life Sciences' Invested Capital history spans 5 years, with the latest figure at $88.3 million for Q3 2025.

  • For Q3 2025, Invested Capital fell 36.03% year-over-year to $88.3 million; the TTM value through Sep 2025 reached $88.3 million, down 36.03%, while the annual FY2024 figure was $122.1 million, 38.18% down from the prior year.
  • Invested Capital for Q3 2025 was $88.3 million at Kezar Life Sciences, down from $97.1 million in the prior quarter.
  • Across five years, Invested Capital topped out at $307.4 million in Q2 2022 and bottomed at $88.3 million in Q3 2025.
  • The 5-year median for Invested Capital is $170.4 million (2024), against an average of $185.5 million.
  • The largest annual shift saw Invested Capital soared 145.38% in 2022 before it crashed 38.95% in 2024.
  • A 5-year view of Invested Capital shows it stood at $206.9 million in 2021, then skyrocketed by 35.28% to $279.9 million in 2022, then fell by 29.41% to $197.6 million in 2023, then plummeted by 38.18% to $122.1 million in 2024, then fell by 27.74% to $88.3 million in 2025.
  • Per Business Quant, the three most recent readings for KZR's Invested Capital are $88.3 million (Q3 2025), $97.1 million (Q2 2025), and $108.3 million (Q1 2025).